The study by Singh et al. [41] found that GLP-1 receptor agonists significantly reduce the risk of myocardial infarction in patients with overweight or obesity (OR 0.72, 95% CI 0.61–0.85), whereas our study revealed that semaglutide does not increase the risk of myocardial infarction (RR 0. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.